

Howard L Mcleod

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6704587/publications.pdf>

Version: 2024-02-01

498
papers

30,885
citations

5782

84
h-index

7234

158
g-index

517
all docs

517
docs citations

517
times ranked

33454
citing authors

#	ARTICLE	IF	CITATIONS
1	Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients. <i>British Journal of Cancer</i> , 2022, 126, 265-274.	2.9	8
2	UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients. <i>European Journal of Cancer</i> , 2022, 162, 148-157.	1.3	27
3	Comparison of FDA Table of Pharmacogenetic Associations and Clinical Pharmacogenetics Implementation Consortium guidelines. <i>American Journal of Health-System Pharmacy</i> , 2022, 79, 993-1005.	0.5	27
4	Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance). <i>Clinical Cancer Research</i> , 2021, 27, 267-275.	3.2	13
5	A Type 2 Diabetes Subtype Responsive to ACCORD Intensive Glycemia Treatment. <i>Diabetes Care</i> , 2021, 44, 1410-1418.	4.3	10
6	Clinical Use of Propranolol Reduces Biomarkers of Proliferation in Gastric Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 628613.	1.3	10
7	Pharmacogenetic study in gastric cancer patients treated with adjuvant fluorouracil/leucovorin or epirubicin/cisplatin/fluorouracil before and after chemoradiation on CALGB 80101 (Alliance). <i>Pharmacogenetics and Genomics</i> , 2021, Publish Ahead of Print, 215-220.	0.7	2
8	High-throughput screening and genome-wide analyses of 44 anticancer drugs in the 1000 Genomes cell lines reveals an association of the NQO1 gene with the response of multiple anticancer drugs. <i>PLoS Genetics</i> , 2021, 17, e1009732.	1.5	6
9	Effect of Physician-Pharmacist Participation in the Management of Ambulatory Cancer Pain Through a Digital Health Platform: Randomized Controlled Trial. <i>JMIR MHealth and UHealth</i> , 2021, 9, e24555.	1.8	11
10	β ₂ -adrenergic receptor inhibition enhances oncolytic herpes virus propagation through STAT3 activation in gastric cancer. <i>Cell and Bioscience</i> , 2021, 11, 174.	2.1	4
11	Identification of Targetable Gene Fusions and Structural Rearrangements to Foster Precision Medicine in KRAS Wild-Type Pancreatic Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 65-74.	1.5	20
12	The need to shift pharmacogenetic research from candidate gene to genome-wide association studies. <i>Pharmacogenomics</i> , 2021, 22, 1143-1150.	0.6	7
13	β ₂ -Adrenergic Receptor Inhibitor and Oncolytic Herpesvirus Combination Therapy Shows Enhanced Antitumoral and Antiangiogenic Effects on Colorectal Cancer. <i>Frontiers in Pharmacology</i> , 2021, 12, 735278.	1.6	3
14	Analytics of the clinical implementation of pharmacogenomics testing in 12,758 individuals. <i>Clinical and Translational Medicine</i> , 2021, 11, e586.	1.7	5
15	Race and smoking status associated with paclitaxel drug response in patient-derived lymphoblastoid cell lines. <i>Pharmacogenetics and Genomics</i> , 2021, 31, 48-52.	0.7	0
16	Assessment of Adverse Events and Their Ability to Discriminate Response to Anti-PD-1/PD-L1 Antibody Immunotherapy. <i>Journal of Clinical Oncology</i> , 2020, 38, 103-104.	0.8	9
17	Prospective CYP2C19 Guided Voriconazole Prophylaxis in Patients With Neutropenic Acute Myeloid Leukemia Reduces the Incidence of Subtherapeutic Antifungal Plasma Concentrations. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 563-570.	2.3	27
18	Clarity Also Needed for Direct-to-Consumer Pharmacogenetic Tests. <i>Journal of Clinical Oncology</i> , 2020, 38, 283-284.	0.8	2

#	ARTICLE	IF	CITATIONS
19	Propranolol Suppresses the Growth of Colorectal Cancer Through Simultaneously Activating Autologous CD8 ⁺ T Cells and Inhibiting Tumor AKT/MAPK Pathway. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 606-615.	2.3	25
20	Genomewide Meta-Analysis Validates a Role for S1PR1 in Microtubule Targeting Agent-Induced Sensory Peripheral Neuropathy. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 625-634.	2.3	25
21	Clinical Cohort Analysis of Germline EGFR T790M Demonstrates Penetrance Across Ethnicities and Races, Sexes, and Ages. <i>JCO Precision Oncology</i> , 2020, 4, 170-175.	1.5	10
22	Pharmacokinetics for the prescriber. <i>Medicine</i> , 2020, 48, 433-438.	0.2	2
23	High levels of tumor-infiltrating lymphocytes showed better clinical outcomes in FOLFOX-treated gastric cancer patients. <i>Pharmacogenomics</i> , 2020, 21, 751-759.	0.6	3
24	Abstract 3226: Facilitating personalized medicine with cloud-based storage and analytics. , 2020, , .		0
25	β-blockers inhibit the viability of breast cancer cells by regulating the ERK/COX2 signaling pathway and the drug response is affected by ADRB2 single-nucleotide polymorphisms. <i>Oncology Reports</i> , 2019, 41, 341-350.	1.2	19
26	Geographic variation in molecular subtype for gastric adenocarcinoma. <i>Gut</i> , 2019, 68, 1340-1341.	6.1	8
27	Pharmacogenomics. <i>Lancet, The</i> , 2019, 394, 521-532.	6.3	261
28	Opportunities, resources, and techniques for implementing genomics in clinical care. <i>Lancet, The</i> , 2019, 394, 511-520.	6.3	53
29	Synergistic Chemotherapy Drug Response Is a Genetic Trait in Lymphoblastoid Cell Lines. <i>Frontiers in Genetics</i> , 2019, 10, 829.	1.1	5
30	Probabilistic medicine: a pre-emptive approach is needed for cancer therapeutic risk mitigation. <i>Biomarkers in Medicine</i> , 2019, 13, 987-990.	0.6	2
31	Rates and Risk of Atrial Arrhythmias in Patients Treated With Ibrutinib Compared With Cytotoxic Chemotherapy. <i>American Journal of Cardiology</i> , 2019, 124, 539-544.	0.7	44
32	Influence of genetic variation in the vitamin D pathway on plasma 25-hydroxyvitamin D3 levels and survival among patients with metastatic colorectal cancer. <i>Cancer Causes and Control</i> , 2019, 30, 757-765.	0.8	4
33	Adherence to Adjuvant Imatinib Therapy in Patients with Gastrointestinal Stromal Tumor in Clinical Practice: A Cross-Sectional Study. <i>Chemotherapy</i> , 2019, 64, 197-204.	0.8	13
34	Genomic Medicine Year in Review: 2019. <i>American Journal of Human Genetics</i> , 2019, 105, 1072-1075.	2.6	10
35	An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance). <i>Pharmacogenetics and Genomics</i> , 2019, 29, 123-131.	0.7	4
36	The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy. <i>Clinical Cancer Research</i> , 2019, 25, 5961-5971.	3.2	118

#	ARTICLE	IF	CITATIONS
37	Prioritization of Therapy Options for a Patient With High Tumor Mutation Burden and Microsatellite Instability but No Clinical Benefit From Immunotherapy. <i>JCO Precision Oncology</i> , 2019, 3, 1-7.	1.5	1
38	Pharmacogenomics: Success and Challenges. , 2019, , 595-606.		0
39	A Pharmacogenetic Prediction Model of Progression-Free Survival in Breast Cancer using Genome-Wide Genotyping Data from CALGB 40502 (Alliance). <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 738-745.	2.3	11
40	ARID1a as a marker of prognosis and increased sensitivity to CDK4/6, mTOR 1/2 and Src homology region 2 phosphatase (SHP 1/2) inhibitors in breast cancer (BC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 1082-1082.	0.8	2
41	Economic benefits of adaptive abiraterone therapy for advanced prostate cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, e18343-e18343.	0.8	2
42	Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and Projects. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 778-786.	2.3	110
43	Genetic Variants in <i>CPA6</i> and <i>PRPF31</i> Are Associated With Variation in Response to Metformin in Individuals With Type 2 Diabetes. <i>Diabetes</i> , 2018, 67, 1428-1440.	0.3	32
44	Avoidance of Severe Cutaneous Adverse Drug Events as a First Step in Precision Neurology. <i>JAMA Neurology</i> , 2018, 75, 793.	4.5	1
45	Value of Supportive Care Pharmacogenomics in Oncology Practice. <i>Oncologist</i> , 2018, 23, 956-964.	1.9	24
46	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for <i>CYP2D6</i> and Tamoxifen Therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 770-777.	2.3	244
47	The pharmacogenetics of medications used in general anesthesia. <i>Pharmacogenomics</i> , 2018, 19, 285-298.	0.6	14
48	Design and rationale for the precision medicine guided treatment for cancer pain pragmatic clinical trial. <i>Contemporary Clinical Trials</i> , 2018, 68, 7-13.	0.8	16
49	Prediction of chemotherapy-induced nausea and vomiting from patient-reported and genetic risk factors. <i>Supportive Care in Cancer</i> , 2018, 26, 2911-2918.	1.0	16
50	Genetic Variants in <i>HSD17B3</i> , <i>SMAD3</i> , and <i>IPO11</i> Impact Circulating Lipids in Response to Fenofibrate in Individuals With Type 2 Diabetes. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 712-721.	2.3	30
51	Research Directions in Genetic Predispositions to Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 390-394.	2.3	15
52	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 210-216.	2.3	407
53	The impact of skeletal muscle on the pharmacokinetics and toxicity of 5-fluorouracil in colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 413-417.	1.1	34
54	Role for Nucleotide Excision Repair Gene Variants in Oxaliplatin-Induced Peripheral Neuropathy. <i>JCO Precision Oncology</i> , 2018, 2, 1-18.	1.5	1

#	ARTICLE	IF	CITATIONS
55	Genetic variation determines VEGF-A plasma levels in cancer patients. <i>Scientific Reports</i> , 2018, 8, 16332.	1.6	10
56	The Future of Radiation Oncology in Soft Tissue Sarcoma. <i>Cancer Control</i> , 2018, 25, 107327481881550.	0.7	6
57	When will clinical trials finally reflect diversity?. <i>Nature</i> , 2018, 557, 157-159.	13.7	96
58	Genome-scale analysis identifies SERPINE1 and SPARC as diagnostic and prognostic biomarkers in gastric cancer. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 6969-6980.	1.0	64
59	Demographic Composition of Select Oncologic New Molecular Entities Approved by the FDA Between 2008 and 2017. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 940-948.	2.3	15
60	The relationship between miR-302b and EphA2 and their clinical significance in gastric cancer. <i>Journal of Cancer</i> , 2018, 9, 3109-3116.	1.2	9
61	Clinical and pharmacogenetics associated with recovery time from general anesthesia. <i>Pharmacogenomics</i> , 2018, 19, 1111-1123.	0.6	4
62	The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation. <i>PLoS ONE</i> , 2018, 13, e0202272.	1.1	13
63	Identification of a Genomic Region between <i>SLC29A1</i> and <i>HSP90AB1</i> Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). <i>Clinical Cancer Research</i> , 2018, 24, 4734-4744.	3.2	14
64	Immunoclassification characterized by CD8 and PD-L1 expression is associated with the clinical outcome of gastric cancer patients. <i>Oncotarget</i> , 2018, 9, 12164-12173.	0.8	16
65	CYP2C19-guided voriconazole prophylaxis in neutropenic AML patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, 6594-6594.	0.8	0
66	The influence of Neanderthal alleles on cytotoxic response. <i>PeerJ</i> , 2018, 6, e5691.	0.9	1
67	Discordance of Somatic Mutations Between Asian and Caucasian Patient Populations with Gastric Cancer. <i>Molecular Diagnosis and Therapy</i> , 2017, 21, 179-185.	1.6	28
68	Strategies for integrating personalized medicine into healthcare practice. <i>Personalized Medicine</i> , 2017, 14, 141-152.	0.8	93
69	American Society of Clinical Oncology Value Framework: Importance of Accurate Toxicity Data. <i>Journal of Clinical Oncology</i> , 2017, 35, 1133-1134.	0.8	6
70	Pharmacoepidemiology of Clinically Relevant Hypothyroidism and Hypertension from Sunitinib and Sorafenib. <i>Oncologist</i> , 2017, 22, 208-212.	1.9	11
71	Quantitation of Targetable Somatic Mutations Among Patients Evaluated by a Personalized Medicine Clinical Service: Considerations for Off-Label Drug Use. <i>Pharmacotherapy</i> , 2017, 37, 1043-1051.	1.2	6
72	Key Lessons Learned from Moffitt's Molecular Tumor Board: The Clinical Genomics Action Committee Experience. <i>Oncologist</i> , 2017, 22, 144-151.	1.9	74

#	ARTICLE	IF	CITATIONS
73	Clinical Response to Pazopanib in a Patient With KDR-Mutated Metastatic Basal Cell Carcinoma. <i>JAMA Dermatology</i> , 2017, 153, 607.	2.0	11
74	Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study. <i>Lancet Oncology</i> , The, 2017, 18, 112-121.	5.1	249
75	Incidence and Triggers of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in a Large Cancer Patient Cohort. <i>Journal of Investigative Dermatology</i> , 2017, 137, 2021-2023.	0.3	18
76	Pharmacogenetics and Pharmacogenomics. , 2017, , 89-107.		3
77	EBV infection and MSI status significantly influence the clinical outcomes of gastric cancer patients. <i>Clinica Chimica Acta</i> , 2017, 471, 216-221.	0.5	21
78	Bedside Back to Bench: Building Bridges between Basic and Clinical Genomic Research. <i>Cell</i> , 2017, 169, 6-12.	13.5	103
79	A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study. <i>Lancet Oncology</i> , The, 2017, 18, 202-211.	5.1	377
80	Comprehensive assessment of cytochromes P450 and transporter genetics with endoxifen concentration during tamoxifen treatment. <i>Pharmacogenetics and Genomics</i> , 2017, 27, 402-409.	0.7	14
81	Prospect for immune checkpoint blockade: dynamic and comprehensive monitorings pave the way. <i>Pharmacogenomics</i> , 2017, 18, 1299-1304.	0.6	4
82	Sink or Collaborate: How the Immersive Model Has Helped Address Typical Adolescent and Young Adult Barriers at a Single Institution and Kept the Adolescent and Young Adult Program Afloat. <i>Journal of Adolescent and Young Adult Oncology</i> , 2017, 6, 503-511.	0.7	14
83	miR-302b inhibits tumorigenesis by targeting EphA2 via Wnt/ β -catenin/EMT signaling cascade in gastric cancer. <i>BMC Cancer</i> , 2017, 17, 886.	1.1	49
84	The impact of sarcopenia on toxicity and pharmacokinetics of 5-fluorouracil (5FU) in colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 633-633.	0.8	3
85	Tumor exome sequencing and copy number alterations reveal potential predictors of intrinsic resistance to multi-targeted tyrosine kinase inhibitors. <i>Oncotarget</i> , 2017, 8, 115114-115127.	0.8	1
86	Common and rare genetic markers of lipid variation in subjects with type 2 diabetes from the ACCORD clinical trial. <i>PeerJ</i> , 2017, 5, e3187.	0.9	11
87	The pan-cancer, pan-biomarker landscape for precision immuno-oncology.. <i>Journal of Clinical Oncology</i> , 2017, 35, 43-43.	0.8	1
88	Incidence and average cost per toxicity in patients treated with nivolumab.. <i>Journal of Clinical Oncology</i> , 2017, 35, 93-93.	0.8	0
89	Pan-cancer opportunities for off-label immunotherapy based on nonsynonymous mutation burden.. <i>Journal of Clinical Oncology</i> , 2017, 35, 14-14.	0.8	0
90	Comparison of incidence and average cost per toxicity in patients treated with nivolumab and pembrolizumab.. <i>Journal of Clinical Oncology</i> , 2017, 35, e18292-e18292.	0.8	0

#	ARTICLE	IF	CITATIONS
91	Abstract 4567: Immunoclassification of gastric cancer in the context of clinical outcome. , 2017, , .		0
92	Abstract 1186: Propranolol could overcome BRAF inhibitors resistance by multiple mechanisms in melanoma. , 2017, , .		0
93	Level of burden of supportive care-relevant pharmacogenetic markers in general population.. Journal of Clinical Oncology, 2017, 35, 221-221.	0.8	0
94	The pharmacogenomics of drug resistance to protein kinase inhibitors. Drug Resistance Updates, 2016, 28, 28-42.	6.5	24
95	Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity. Oncologist, 2016, 21, 795-803.	1.9	42
96	Pharmacokinetics for the prescriber. Medicine, 2016, 44, 407-411.	0.2	4
97	Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a <i>VAC14</i> Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy. Clinical Cancer Research, 2016, 22, 4890-4900.	3.2	46
98	Somatic cancer variant curation and harmonization through consensus minimum variant level data. Genome Medicine, 2016, 8, 117.	3.6	61
99	A comparison of DMET Plus microarray and genome-wide technologies by assessing population substructure. Pharmacogenetics and Genomics, 2016, 26, 147-153.	0.7	9
100	The potential anticancer effect of beta-blockers and the genetic variations involved in the interindividual difference. Pharmacogenomics, 2016, 17, 74-9.	0.6	14
101	Clinical implementation of pharmacogenetics. Drug Metabolism and Personalized Therapy, 2016, 31, 9-16.	0.3	21
102	Effects of quercetin on pharmacokinetics of cefprozil in Chinese-Han male volunteers. Xenobiotica, 2016, 46, 896-900.	0.5	7
103	Comparison of genetic variation in drug ADME-related genes in Thais with Caucasian, African and Asian HapMap populations. Journal of Human Genetics, 2016, 61, 119-127.	1.1	25
104	Modeling the cost of immune checkpoint inhibitor-related toxicities.. Journal of Clinical Oncology, 2016, 34, 6627-6627.	0.8	11
105	Propranolol induced G0/G1/S phase arrest and apoptosis in melanoma cells via AKT/MAPK pathway. Oncotarget, 2016, 7, 68314-68327.	0.8	56
106	Breast cancer mutation frequency between smokers and non-smokers.. Journal of Clinical Oncology, 2016, 34, e13015-e13015.	0.8	0
107	Incidence and risk factors for ibrutinib associated atrial fibrillation.. Journal of Clinical Oncology, 2016, 34, e19028-e19028.	0.8	0
108	Assessment of a clinical and genetic algorithm to predict endoxifen concentration.. Journal of Clinical Oncology, 2016, 34, e12021-e12021.	0.8	0

#	ARTICLE	IF	CITATIONS
109	A genome-wide association study (GWAS) of progression-free survival (PFS) in metastatic breast cancer (MBC) patients treated with letrozole (L) with or without bevacizumab (B) in CALGB 40503.. Journal of Clinical Oncology, 2016, 34, 538-538.	0.8	0
110	Abstract 2037: A discovery study to identify clinical and genetic risk factors for bevacizumab (BEV)-related gastrointestinal (GI) hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated on CALGB 90401 (Alliance). , 2016, , .		0
111	Abstract 1409: Is it what's on the inside that counts? Melanoma mutation profiling and outcomes with immunotherapy. , 2016, , .		0
112	Abstract 2992: Propranolol induces G0/G1/S phase arrest and apoptosis in melanoma cells via AKT/MAPK pathway. , 2016, , .		0
113	Abstract 1487: Gene expression and linkage analysis implicates CBLB as a mediator of rituximab resistance. Cancer Research, 2016, 76, 1487-1487.	0.4	0
114	Clonal Hematopoiesis Is Associated with Therapy-Related Myeloid Malignancies in the Elderly. Blood, 2016, 128, 295-295.	0.6	0
115	Clinical Implications of Opioid Pharmacogenomics in Patients with Cancer. Cancer Control, 2015, 22, 426-432.	0.7	24
116	<i>In vivo</i> assessment of the metabolic activity of CYP2D6 diplotypes and alleles. British Journal of Clinical Pharmacology, 2015, 80, 1122-1130.	1.1	40
117	PharmGKB summary. Pharmacogenetics and Genomics, 2015, 25, 622-630.	0.7	25
118	Global implementation of genomic medicine: We are not alone. Science Translational Medicine, 2015, 7, 290ps13.	5.8	146
119	Precision Medicine to Improve the Risk and Benefit of Cancer Care. JAMA - Journal of the American Medical Association, 2015, 313, 803.	3.8	8
120	Heritage-Specific Mechanisms for Cancer Adverse Reactions: One Gene Does Not Explain the World. Journal of Clinical Oncology, 2015, 33, 1230-1231.	0.8	1
121	Budget impact analysis of <i>CYP2C19</i> -guided voriconazole prophylaxis in AML. Journal of Antimicrobial Chemotherapy, 2015, 70, 3124-3126.	1.3	14
122	Accuracy of SNPs to predict risk of HLA alleles associated with drug-induced hypersensitivity events across racial groups. Pharmacogenomics, 2015, 16, 817-824.	0.6	18
123	Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance). Cancer, 2015, 121, 1025-1031.	2.0	32
124	Fast and frugal trees: translating population-based pharmacogenomics to medication prioritization. Personalized Medicine, 2015, 12, 117-128.	0.8	3
125	Pharmacogenomic assessment of Mexican and Peruvian populations. Pharmacogenomics, 2015, 16, 441-448.	0.6	19
126	Participation in Cancer Pharmacogenomic Studies: A Study of 8456 Patients Registered to Clinical Trials in the Cancer and Leukemia Group B (Alliance). Journal of the National Cancer Institute, 2015, 107, djv188.	3.0	6

#	ARTICLE	IF	CITATIONS
127	Single-Nucleotide Polymorphisms in Cytochrome P450 2E1 (CYP2E1) 3' Untranslated Region Affect the Regulation of CYP2E1 by miR-570. <i>Drug Metabolism and Disposition</i> , 2015, 43, 1450-1457.	1.7	29
128	Evaluating the role of admixture in cancer therapy via <i>in vitro</i> drug response and multivariate genome-wide associations. <i>Pharmacogenomics</i> , 2015, 16, 1451-1463.	0.6	8
129	Abstract LB-246: Evaluating the role of admixture in cancer therapy via <i>in vitro</i> drug response and multivariate genome-wide associations. , 2015, , .		1
130	A genome-wide association study (GWAS) of overall survival (OS) in 609 metastatic colorectal cancer (mCRC) patients treated with chemotherapy and biologics in CALGB 80405. <i>Journal of Clinical Oncology</i> , 2015, 33, 3599-3599.	0.8	1
131	Potential germline relevance of tumor testing and the need for genetic referral. <i>Journal of Clinical Oncology</i> , 2015, 33, e12552-e12552.	0.8	2
132	Abstract P1-03-02: CYP2D6 intermediate metabolizers includes patient groups with distinct metabolic activity. , 2015, , .		1
133	Budget impact analysis of <i>CYP2C19</i> genotyping to guide voriconazole prophylaxis in acute myeloid leukemia (AML). <i>Journal of Clinical Oncology</i> , 2015, 33, e17777-e17777.	0.8	0
134	The landscape for genetic eligibility to basket clinical trials. <i>Journal of Clinical Oncology</i> , 2015, 33, 1530-1530.	0.8	0
135	Thymidylate Synthase Genotype-Directed Chemotherapy for Patients with Gastric and Gastroesophageal Junction Cancers. <i>PLoS ONE</i> , 2014, 9, e107424.	1.1	6
136	Exploring the Distribution of Genetic Markers of Pharmacogenomics Relevance in Brazilian and Mexican Populations. <i>PLoS ONE</i> , 2014, 9, e112640.	1.1	67
137	Clinically relevant cancer biomarkers and pharmacogenetic assays. <i>Journal of Oncology Pharmacy Practice</i> , 2014, 20, 65-72.	0.5	12
138	Genome-wide association and pharmacological profiling of 29 anticancer agents using lymphoblastoid cell lines. <i>Pharmacogenomics</i> , 2014, 15, 137-146.	0.6	27
139	Using Pharmacogene Polymorphism Panels to Detect Germline Pharmacodynamic Markers in Oncology. <i>Clinical Cancer Research</i> , 2014, 20, 2530-2540.	3.2	21
140	A Community-Based Multicenter Trial of Pharmacokinetically Guided 5-Fluorouracil Dosing for Personalized Colorectal Cancer Therapy. <i>Oncologist</i> , 2014, 19, 959-965.	1.9	36
141	Genetic Markers of Toxicity From Capecitabine and Other Fluorouracil-Based Regimens: Investigation in the QUASAR2 Study, Systematic Review, and Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2014, 32, 1031-1039.	0.8	216
142	Personalizing Medicine in Geriatric Oncology. <i>Journal of Clinical Oncology</i> , 2014, 32, 2581-2586.	0.8	37
143	Characterizing genetic variants for clinical action. <i>American Journal of Medical Genetics, Part C: Seminars in Medical Genetics</i> , 2014, 166, 93-104.	0.7	50
144	Application of next generation sequencing to CEPH cell lines to discover variants associated with FDA approved chemotherapeutics. <i>BMC Research Notes</i> , 2014, 7, 360.	0.6	5

#	ARTICLE	IF	CITATIONS
145	Genetic heterogeneity beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy. <i>Breast Cancer Research and Treatment</i> , 2014, 145, 245-254.	1.1	41
146	Epigenetic perspectives on cancer chemotherapy response. <i>Pharmacogenomics</i> , 2014, 15, 699-715.	0.6	11
147	Cancer pharmacogenomics, adoption by oncologists and patient benefit. <i>Personalized Medicine</i> , 2014, 11, 143-153.	0.8	14
148	Implementation of a pharmacogenomics service in a community pharmacy. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2014, 54, 172-180.	0.7	77
149	Does increasing the daily tamoxifen dose in patients with diminished CYP2D6 activity increase toxicity?. <i>Journal of Clinical Oncology</i> , 2014, 32, 561-561.	0.8	2
150	Germline Variation in Colorectal Risk Loci Does Not Influence Treatment Effect or Survival in Metastatic Colorectal Cancer. <i>PLoS ONE</i> , 2014, 9, e94727.	1.1	4
151	Pharmacogenomics and Cancer Therapy: Somatic and Germline Polymorphisms. <i>Cancer Drug Discovery and Development</i> , 2014, , 255-272.	0.2	0
152	Final results of the UGT1A1-based dose modification of irinotecan and its impact on rates of severe neutropenia and hospitalization.. <i>Journal of Clinical Oncology</i> , 2014, 32, 461-461.	0.8	0
153	Bevacizumab (BEV) and risk of hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients treated on CALGB 90401 (ALLIANCE).. <i>Journal of Clinical Oncology</i> , 2014, 32, e16061-e16061.	0.8	0
154	A genome-wide association study (GWAS) of docetaxel-induced neutropenia in CALGB 90401/60404 (Alliance).. <i>Journal of Clinical Oncology</i> , 2014, 32, 9612-9612.	0.8	0
155	Abstract 3841: Bevacizumab (BEV) and risk of arterial (ATE) and venous thromboembolism (VTE) in metastatic castration-resistant prostate cancer (mCRPC) patients treated on CALGB 90401(ALLIANCE)., 2014, , .		0
156	Gastric cancer pharmacogenetics: progress or old tripe?. <i>Pharmacogenomics</i> , 2013, 14, 1053-1064.	0.6	18
157	Impact of genotype-guided dosing on anticoagulation visits for adults starting warfarin: a randomized controlled trial. <i>Pharmacogenomics</i> , 2013, 14, 1593-1603.	0.6	47
158	Cancer Pharmacogenomics: Early Promise, But Concerted Effort Needed. <i>Science</i> , 2013, 339, 1563-1566.	6.0	142
159	Genomic Medicine: A Decade of Successes, Challenges, and Opportunities. <i>Science Translational Medicine</i> , 2013, 5, 189sr4.	5.8	197
160	Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 139, 135-143.	1.1	16
161	Genome-wide studies in pharmacogenomics: harnessing the power of extreme phenotypes. <i>Pharmacogenomics</i> , 2013, 14, 337-339.	0.6	22
162	Current pharmacogenomic studies on hERG potassium channels. <i>Trends in Molecular Medicine</i> , 2013, 19, 227-238.	3.5	30

#	ARTICLE	IF	CITATIONS
163	Does Pharmacogenomics Account for Variability in Control of Acute Chemotherapy-Induced Nausea and Vomiting with 5-Hydroxytryptamine Type 3 Receptor Antagonists?. <i>Current Oncology Reports</i> , 2013, 15, 276-285.	1.8	18
164	Pharmacogenetics and Pharmacogenomics. , 2013, , 362-371.		0
165	Exome Resequencing Identifies Potential Tumor-Suppressor Genes that Predispose to Colorectal Cancer. <i>Human Mutation</i> , 2013, 34, 1026-1034.	1.1	48
166	Use of pharmacogenetics for predicting cancer prognosis and treatment exposure, response and toxicity. <i>Journal of Human Genetics</i> , 2013, 58, 346-352.	1.1	52
167	Implications of genome-wide association studies in cancer therapeutics. <i>British Journal of Clinical Pharmacology</i> , 2013, 76, 370-380.	1.1	21
168	Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy. <i>Pharmacogenomics</i> , 2013, 14, 555-574.	0.6	24
169	VKORC1 Asp36Tyr geographic distribution and its impact on warfarin dose requirements in Egyptians. <i>Thrombosis and Haemostasis</i> , 2013, 109, 1045-1050.	1.8	24
170	Pharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicity. <i>Pharmacogenomics</i> , 2013, 14, 205-213.	0.6	35
171	Cumulative Genetic Risk Predicts Platinum/Taxane-Induced Neurotoxicity. <i>Clinical Cancer Research</i> , 2013, 19, 5769-5776.	3.2	27
172	Nomenclature for alleles of the thiopurine methyltransferase gene. <i>Pharmacogenetics and Genomics</i> , 2013, 23, 242-248.	0.7	104
173	The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia. <i>Pharmacogenetics and Genomics</i> , 2013, 23, 29-33.	0.7	24
174	Application of pharmacokinetic (PK)-guided 5-fluorouracil (FU) in clinical practice.. <i>Journal of Clinical Oncology</i> , 2013, 31, 2595-2595.	0.8	2
175	Analysis of innate and acquired resistance to anti-CD20 antibodies in malignant and nonmalignant B cells. <i>PeerJ</i> , 2013, 1, e31.	0.9	27
176	Prognostic Markers in Colon Cancer. , 2013, , 131-162.		0
177	Evaluating variability in fluorouracil (FU) exposure in obese and non-obese patients with colorectal cancer using full weight-based dosing.. <i>Journal of Clinical Oncology</i> , 2013, 31, 409-409.	0.8	5
178	Participation in cancer pharmacogenomic studies in 8,456 patients registered to Cancer and Leukemia Group B (Alliance) clinical trials.. <i>Journal of Clinical Oncology</i> , 2013, 31, 6501-6501.	0.8	0
179	A genome-wide association study (GWAS) of docetaxel-induced peripheral neuropathy in CALGB 90401 (Alliance).. <i>Journal of Clinical Oncology</i> , 2013, 31, 11053-11053.	0.8	0
180	Tamoxifen and CYP2D6: A Contradiction of Data. <i>Oncologist</i> , 2012, 17, 620-630.	1.9	71

#	ARTICLE	IF	CITATIONS
181	Exploration of CYP450 and drug transporter genotypes and correlations with nevirapine exposure in Malawians. <i>Pharmacogenomics</i> , 2012, 13, 113-121.	0.6	27
182	Knowledge, attitudes and education of pharmacists regarding pharmacogenetic testing. <i>Personalized Medicine</i> , 2012, 9, 19-27.	0.8	66
183	A Genome-Wide Association Study of Overall Survival in Pancreatic Cancer Patients Treated with Gemcitabine in CALGB 80303. <i>Clinical Cancer Research</i> , 2012, 18, 577-584.	3.2	91
184	Exploratory planning and implementation of a pilot pharmacogenetic program in a community pharmacy. <i>Pharmacogenomics</i> , 2012, 13, 955-962.	0.6	26
185	A Genome-Wide Association Study Identifies Novel Loci for Paclitaxel-Induced Sensory Peripheral Neuropathy in CALGB 40101. <i>Clinical Cancer Research</i> , 2012, 18, 5099-5109.	3.2	183
186	Assessing the utility of whole genome amplified DNA as a template for DMET Plus array. <i>Clinical Chemistry and Laboratory Medicine</i> , 2012, 50, 1329-34.	1.4	8
187	Modeling the 5-Fluorouracil Area Under the Curve Versus Dose Relationship to Develop a Pharmacokinetic Dosing Algorithm for Colorectal Cancer Patients Receiving FOLFOX6. <i>Oncologist</i> , 2012, 17, 296-302.	1.9	75
188	Re: CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women With Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial. <i>Journal of the National Cancer Institute</i> , 2012, 104, 1264-1264.	3.0	70
189	A genome-wide association analysis of temozolomide response using lymphoblastoid cell lines shows a clinically relevant association with MGMT. <i>Pharmacogenetics and Genomics</i> , 2012, 22, 796-802.	0.7	32
190	Novel tagging SNP rs1495741 and 2-SNPs (rs1041983 and rs1801280) yield a high prediction of the NAT2 genotype in HapMap samples. <i>Pharmacogenetics and Genomics</i> , 2012, 22, 322-324.	0.7	12
191	Making pharmacogenetic testing a reality in a community pharmacy. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2012, 52, e259-e265.	0.7	34
192	Use of CYP2D6 genotyping in practice: tamoxifen dose adjustment. <i>Pharmacogenomics</i> , 2012, 13, 691-697.	0.6	27
193	Genetic Tailoring of Pharmacotherapy in Heart Failure: Optimize the Old, While We Wait for Something New. <i>Journal of Cardiac Failure</i> , 2012, 18, 338-349.	0.7	22
194	Multivariate methods and software for association mapping in dose-response genome-wide association studies. <i>BioData Mining</i> , 2012, 5, 21.	2.2	17
195	CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 401-410.	1.1	81
196	Genome-wide association mapping of loci for antipsychotic-induced extrapyramidal symptoms in mice. <i>Mammalian Genome</i> , 2012, 23, 322-335.	1.0	31
197	Pharmacokinetics for the prescriber. <i>Medicine</i> , 2012, 40, 357-361.	0.2	0
198	Differentially expressed genes in human peripheral blood as potential markers for statin response. <i>Journal of Molecular Medicine</i> , 2012, 90, 201-211.	1.7	6

#	ARTICLE	IF	CITATIONS
199	Investigating the utilization of pharmacokinetic-guided fluorouracil in colorectal cancer.. Journal of Clinical Oncology, 2012, 30, e13109-e13109.	0.8	1
200	Association of Eleven Common, Low-Penetrance Colorectal Cancer Susceptibility Genetic Variants at Six Risk Loci with Clinical Outcome. PLoS ONE, 2012, 7, e41954.	1.1	17
201	KRAS mutation as a prognostic factor in patients undergoing hepatic resection for metastatic colorectal cancer.. Journal of Clinical Oncology, 2012, 30, 444-444.	0.8	0
202	Interrogation of polymorphisms in drug metabolism or transport genes and peripheral neuropathy during paclitaxel treatment.. Journal of Clinical Oncology, 2012, 30, 10515-10515.	0.8	0
203	Genotype-Guided Tamoxifen Dosing Increases Active Metabolite Exposure in Women With Reduced CYP2D6 Metabolism: A Multicenter Study. Journal of Clinical Oncology, 2011, 29, 3232-3239.	0.8	173
204	Pharmacogenetics and rational drug use around the world. Pharmacogenomics, 2011, 12, 897-905.	0.6	18
205	Copy number variants in pharmacogenetic genes. Trends in Molecular Medicine, 2011, 17, 244-251.	3.5	90
206	PharmGKB summary. Pharmacogenetics and Genomics, 2011, 21, 237-242.	0.7	93
207	A comparison of association methods for cytotoxicity mapping in pharmacogenomics. Frontiers in Genetics, 2011, 2, 86.	1.1	14
208	Identification and Replication of Loci Involved in Camptothecin-Induced Cytotoxicity Using CEPH Pedigrees. PLoS ONE, 2011, 6, e17561.	1.1	14
209	The NQO1*2/*2 polymorphism is associated with poor overall survival in patients following resection of stages II and IIIa non-small cell lung cancer. Oncology Reports, 2011, 25, 1765-72.	1.2	21
210	Doxorubicin pathways. Pharmacogenetics and Genomics, 2011, 21, 440-446.	0.7	1,167
211	Pharmacogenomic Contribution to Drug Response. Cancer Journal (Sudbury, Mass), 2011, 17, 80-88.	1.0	16
212	PharmGKB summary. Pharmacogenetics and Genomics, 2011, 21, 679-686.	0.7	120
213	RNA expression of the molecular signature genes for metastasis in colorectal cancer. Oncology Reports, 2011, 25, 1321-7.	1.2	4
214	Pharmacogenomics in a community pharmacy: ACT now. Journal of the American Pharmacists Association: JAPhA, 2011, 51, 189-193.	0.7	31
215	Preemptive Pharmacogenetic Testing: Insufficient Data Equal Unsatisfactory Guidance. Annals of Internal Medicine, 2011, 154, 842.	2.0	9
216	A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies. Cancer Chemotherapy and Pharmacology, 2011, 67, 1225-1237.	1.1	58

#	ARTICLE	IF	CITATIONS
217	Pharmacogenetic tests in cancer chemotherapy: what physicians should know for clinical application. <i>Journal of Pathology</i> , 2011, 223, 15-27.	2.1	41
218	Pharmacogenomic characterization of US FDA-approved cytotoxic drugs. <i>Pharmacogenomics</i> , 2011, 12, 1407-1415.	0.6	44
219	Genomic Profiling in CEPH Cell Lines Distinguishes between the Camptothecins and Indenoisoquinolines. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 1839-1845.	1.9	10
220	Thymidylate Synthase Genotype-Directed Neoadjuvant Chemoradiation for Patients With Rectal Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 875-883.	0.8	58
221	Genomics and Drug Response. <i>New England Journal of Medicine</i> , 2011, 364, 1144-1153.	13.9	552
222	Systems pharmacology assessment of the 5-fluorouracil pathway. <i>Pharmacogenomics</i> , 2011, 12, 341-350.	0.6	42
223	Can pharmacogenomics improve malaria drug policy?. <i>Bulletin of the World Health Organization</i> , 2011, 89, 838-845.	1.5	26
224	Genomewide Analysis of Inherited Variation Associated with Phosphorylation of PI3K/AKT/mTOR Signaling Proteins. <i>PLoS ONE</i> , 2011, 6, e24873.	1.1	7
225	The Predictive Value of FCGR3A Polymorphism on Clinical Outcomes of Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP Chemotherapy. <i>Blood</i> , 2011, 118, 89-89.	0.6	0
226	Ex-Vivo Modeling for Heritability Assessment and Genetic Mapping in Pharmacogenomics. <i>Proceedings</i> , 2011, 2011, 306-318.	0.3	1
227	Vascular endothelial growth factor pathway. <i>Pharmacogenetics and Genomics</i> , 2010, 20, 346-349.	0.7	18
228	Thiopurine pathway. <i>Pharmacogenetics and Genomics</i> , 2010, 20, 573-574.	0.7	89
229	Pharmacogenetic Predictors of Adverse Events and Response to Chemotherapy in Metastatic Colorectal Cancer: Results From North American Gastrointestinal Intergroup Trial N9741. <i>Journal of Clinical Oncology</i> , 2010, 28, 3227-3233.	0.8	198
230	Using patient DNA to optimize therapy in heart failure patients: a move toward perfection. <i>Heart Failure Reviews</i> , 2010, 15, 183-185.	1.7	1
231	A PPAR α Promoter Variant Impairs ERR-Dependent Transactivation and Decreases Mortality after Acute Coronary Ischemia in Patients with Diabetes. <i>PLoS ONE</i> , 2010, 5, e12584.	1.1	18
232	Cytochrome P450 2C9-CYP2C9. <i>Pharmacogenetics and Genomics</i> , 2010, 20, 277-281.	0.7	205
233	Detection of the G>C SNP and rare mutations in the 28-bp repeat of <i>TYMS</i> using gel-based capillary electrophoresis. <i>Pharmacogenomics</i> , 2010, 11, 1751-1756.	0.6	16
234	Applying the genome to national drug formulary policy in the developing world. <i>Pharmacogenomics</i> , 2010, 11, 633-636.	0.6	19

#	ARTICLE	IF	CITATIONS
235	Race and Methotrexate Pharmacogenetics in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2010, 37, 1064.1-1064.	1.0	5
236	Population Pharmacokinetic Modeling of the Association between 63396Câ€™T Pregnane X Receptor Polymorphism and Unboosted Atazanavir Clearance. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 5242-5250.	1.4	66
237	Cancer Pharmacogenomics and Pharmacoepidemiology: Setting a Research Agenda to Accelerate Translation. <i>Journal of the National Cancer Institute</i> , 2010, 102, 1698-1705.	3.0	40
238	Institutional Profile: UNC Institute for Pharmacogenomics and Individualized Therapy: interdisciplinary research for individual care. <i>Pharmacogenomics</i> , 2010, 11, 13-21.	0.6	1
239	Colorectal Cancer Cell Lines Lack the Molecular Heterogeneity of Clinical Colorectal Tumors. <i>Clinical Colorectal Cancer</i> , 2010, 9, 40-47.	1.0	20
240	Amplification of thymidylate synthetase in metastatic colorectal cancer patients pretreated with 5-fluorouracil-based chemotherapy. <i>European Journal of Cancer</i> , 2010, 46, 3358-3364.	1.3	41
241	Economic Opportunities and Challenges for Pharmacogenomics. <i>Annual Review of Pharmacology and Toxicology</i> , 2010, 50, 423-437.	4.2	55
242	Aromatase Gene Polymorphisms Are Associated with Survival among Patients with Cardiovascular Disease in a Sex-Specific Manner. <i>PLoS ONE</i> , 2010, 5, e15180.	1.1	22
243	Leveraging learning from a phase III colorectal cancer clinical trial: outcomes, methodology, meta-analysis and pharmacogenetics. <i>Transactions of the American Clinical and Climatological Association</i> , 2010, 121, 21-32; discussion 32-3.	0.9	2
244	Platinum neurotoxicity pharmacogenetics. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 10-16.	1.9	500
245	Pharmacogenomic Discovery Using Cell-Based Models. <i>Pharmacological Reviews</i> , 2009, 61, 413-429.	7.1	109
246	A Health Services Research Agenda for Cellular, Molecular and Genomic Technologies in Cancer Care. <i>Public Health Genomics</i> , 2009, 12, 233-244.	0.6	15
247	Using germline genotype in cancer pharmacogenetic studies. <i>Pharmacogenomics</i> , 2009, 10, 489-493.	0.6	33
248	Genome-wide association studies: powerful tools for improving drug safety and efficacy. <i>Pharmacogenomics</i> , 2009, 10, 157-159.	0.6	21
249	Pharmacogenomic genome-wide association studies: lessons learned thus far. <i>Pharmacogenomics</i> , 2009, 10, 161-163.	0.6	53
250	Pharmacodynamic genes do not influence risk of neutropenia in cancer patients treated with moderately high-dose irinotecan. <i>Pharmacogenomics</i> , 2009, 10, 1139-1146.	0.6	11
251	Patterns of pharmacogenetic diversity in African populations: role of ancient and recent history. <i>Pharmacogenomics</i> , 2009, 10, 1413-1422.	0.6	9
252	Pharmacogenomic progress in individualized dosing of key drugs for cancer patients. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 153-162.	12.5	33

#	ARTICLE	IF	CITATIONS
253	NCCTG Study N9741: Leveraging Learning from an NCI Cooperative Group Phase III Trial. <i>Oncologist</i> , 2009, 14, 970-978.	1.9	11
254	Racial Differences in Advanced Colorectal Cancer Outcomes and Pharmacogenetics: A Subgroup Analysis of a Large Randomized Clinical Trial. <i>Journal of Clinical Oncology</i> , 2009, 27, 4109-4115.	0.8	74
255	Japanese-US Common-Arm Analysis of Paclitaxel Plus Carboplatin in Advanced Non-Small-Cell Lung Cancer: A Model for Assessing Population-Related Pharmacogenomics. <i>Journal of Clinical Oncology</i> , 2009, 27, 3540-3546.	0.8	189
256	Pharmacogenetics of breast cancer therapies. <i>Breast</i> , 2009, 18, S59-S63.	0.9	12
257	CYP2D6 and tamoxifen: DNA matters in breast cancer. <i>Nature Reviews Cancer</i> , 2009, 9, 576-586.	12.8	287
258	Biomarkers for Response to Neoadjuvant Chemoradiation for Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 74, 673-688.	0.4	215
259	UGT1A and Irinotecan Toxicity: Keeping It in the Family. <i>Journal of Clinical Oncology</i> , 2009, 27, 2419-2421.	0.8	20
260	Genomics: Applications in mechanism elucidation. <i>Advanced Drug Delivery Reviews</i> , 2009, 61, 369-374.	6.6	9
261	Genetic and clinical factors relating to warfarin dosing. <i>Trends in Pharmacological Sciences</i> , 2009, 30, 375-386.	4.0	126
262	The Pharmacogenetics of Statin Therapy. <i>Journal of the American College of Cardiology</i> , 2009, 54, 1617-1618.	1.2	7
263	Role of Pharmacogenetics as Predictive Biomarkers of Response and/or Toxicity in the Treatment of Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2009, 8, 15-21.	1.0	16
264	Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations. <i>Pharmacogenomics</i> , 2009, 10, 1799-1817.	0.6	100
265	Validation of Clinical Testing for Warfarin Sensitivity. <i>Journal of Molecular Diagnostics</i> , 2009, 11, 216-225.	1.2	53
266	Etoposide pathway. <i>Pharmacogenetics and Genomics</i> , 2009, 19, 552-553.	0.7	41
267	Taxane pathway. <i>Pharmacogenetics and Genomics</i> , 2009, 19, 979-983.	0.7	43
268	Association of thymidylate synthase variants with 5-fluorouracil cytotoxicity. <i>Pharmacogenetics and Genomics</i> , 2009, 19, 399-401.	0.7	21
269	Chemotherapy-induced tumor gene expression changes in human breast cancers. <i>Pharmacogenetics and Genomics</i> , 2009, 19, 181-192.	0.7	32
270	Post-treatment tumor gene expression signatures are more predictive of treatment outcomes than baseline signatures in breast cancer. <i>Pharmacogenetics and Genomics</i> , 2009, 19, 833-842.	0.7	13

#	ARTICLE	IF	CITATIONS
271	Platinum pathway. <i>Pharmacogenetics and Genomics</i> , 2009, 19, 563-564.	0.7	39
272	CANDID: a flexible method for prioritizing candidate genes for complex human traits. <i>Genetic Epidemiology</i> , 2008, 32, 779-790.	0.6	75
273	Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 84, 326-331.	2.3	743
274	Creating and evaluating genetic tests predictive of drug response. <i>Nature Reviews Drug Discovery</i> , 2008, 7, 568-574.	21.5	51
275	Pharmacokinetics for the prescriber. <i>Medicine</i> , 2008, 36, 350-354.	0.2	4
276	Carbamazepine, <i><i>HLA-B*1502</i></i> and risk of Stevensâ€™Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. <i>Pharmacogenomics</i> , 2008, 9, 1543-1546.	0.6	421
277	Knockdown of RNA Binding Protein Musashi-1 Leads to Tumor Regression In Vivo. <i>Gastroenterology</i> , 2008, 134, 1448-1458.e2.	0.6	163
278	Cancer Pharmacogenomics: DNA Genotyping and Gene Expression Profiling to Identify Molecular Determinants of Chemosensitivity. <i>Drug Metabolism Reviews</i> , 2008, 40, 303-315.	1.5	16
279	Celecoxib pre-treatment in human colorectal adenocarcinoma patients is associated with gene expression alterations suggestive of diminished cellular proliferation. <i>European Journal of Cancer</i> , 2008, 44, 1754-1760.	1.3	28
280	Predictive Factors for Response and Toxicity in Chemotherapy: Pharmacogenomics. <i>Seminars in Colon and Rectal Surgery</i> , 2008, 19, 226-230.	0.2	11
281	Validation of Analytic Methods for Biomarkers Used in Drug Development. <i>Clinical Cancer Research</i> , 2008, 14, 5967-5976.	3.2	202
282	Can Inhibiting Dihydropyrimidine Dehydrogenase Limit Hand-Foot Syndrome Caused by Fluoropyrimidines?. <i>Clinical Cancer Research</i> , 2008, 14, 8-13.	3.2	63
283	Irinotecan Pharmacogenetics: Influence of Pharmacodynamic Genes. <i>Clinical Cancer Research</i> , 2008, 14, 1788-1796.	3.2	72
284	<i><i>ABCB1</i></i> (<i><i>MDR 1</i></i>) Polymorphisms and Progression-Free Survival among Women with Ovarian Cancer following Paclitaxel/Carboplatin Chemotherapy. <i>Clinical Cancer Research</i> , 2008, 14, 5594-5601.	3.2	90
285	Will We Ever Be Ready for Blood Levelâ€™Guided Therapy?. <i>Journal of Clinical Oncology</i> , 2008, 26, 2078-2079.	0.8	15
286	wuHMM: a robust algorithm to detect DNA copy number variation using long oligonucleotide microarray data. <i>Nucleic Acids Research</i> , 2008, 36, e41.	6.5	25
287	Interaction between <i><i>PPARA</i></i> genotype and Î²-blocker treatment influences clinical outcomes following acute coronary syndromes. <i>Pharmacogenomics</i> , 2008, 9, 1403-1417.	0.6	16
288	Copy-number analysis of topoisomerase and thymidylate synthase genes in frozen and FFPE DNAs of colorectal cancers. <i>Pharmacogenomics</i> , 2008, 9, 1459-1466.	0.6	24

#	ARTICLE	IF	CITATIONS
289	Ability of whole-genome SNP arrays to capture "must have"™ pharmacogenomic variants. <i>Pharmacogenomics</i> , 2008, 9, 1573-1577.	0.6	27
290	Race does not explain genetic heterogeneity in pharmacogenomic pathways. <i>Pharmacogenomics</i> , 2008, 9, 1639-1645.	0.6	12
291	Structure and characterization of human carboxylesterase 1A1, 1A2, and 1A3 genes. <i>Pharmacogenetics and Genomics</i> , 2008, 18, 911-920.	0.7	69
292	Cell-Based Models to Identify Genetic Variants Contributing to Anticancer Drug Response. , 2008, , 19-31.		0
293	DNA methylotype analysis in colorectal cancer. <i>Oncology Reports</i> , 2008, 20, 921-7.	1.2	7
294	Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2008, 35, 572-9.	1.0	110
295	A High-Resolution Map of Segmental DNA Copy Number Variation in the Mouse Genome. <i>PLoS Genetics</i> , 2007, 3, e3.	1.5	196
296	Primum non nocere: adverse drug events must be taken seriously. <i>Pharmacogenomics</i> , 2007, 8, 311-314.	0.6	13
297	Genetic nondiscrimination legislation: a critical prerequisite for pharmacogenomics data sharing. <i>Pharmacogenomics</i> , 2007, 8, 519-519.	0.6	9
298	Pharmacogenetic Assessment of Toxicity and Outcome After Platinum Plus Taxane Chemotherapy in Ovarian Cancer: The Scottish Randomised Trial in Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 4528-4535.	0.8	213
299	A Novel Duplication Type of CYP2A6 Gene in African-American Population. <i>Drug Metabolism and Disposition</i> , 2007, 35, 515-520.	1.7	42
300	MAGED2: A novel p53-dissociator. <i>International Journal of Oncology</i> , 2007, 31, 1205.	1.4	7
301	D3-02: Updated Paclitaxel-Carboplatin Pharmacogenomic (PG) Analysis of Japan-SWOG Common Arm Study in Advanced Non-Small Cell Lung Cancer (NSCLC). <i>Journal of Thoracic Oncology</i> , 2007, 2, S397.	0.5	0
302	Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation for Locally Advanced Esophageal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2007, 30, 507-513.	0.6	25
303	Connexin37 (GJA4) genotype predicts survival after an acute coronary syndrome. <i>American Heart Journal</i> , 2007, 154, 561-566.	1.2	34
304	Should DPD analysis be required prior to prescribing fluoropyrimidines?. <i>European Journal of Cancer</i> , 2007, 43, 1011-1016.	1.3	102
305	Pharmacogenetics and oncology treatment for breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 119-127.	0.9	40
306	UGT1A1*28 Genotype and Irinotecan-Induced Neutropenia: Dose Matters. <i>Journal of the National Cancer Institute</i> , 2007, 99, 1290-1295.	3.0	436

#	ARTICLE	IF	CITATIONS
307	Identification of NR112 genetic variation using resequencing. <i>European Journal of Clinical Pharmacology</i> , 2007, 63, 547-554.	0.8	31
308	Mechanisms of acquired chemoresistance to 5-fluorouracil and tomudex: thymidylate synthase dependent and independent networks. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 59, 839-845.	1.1	39
309	Genetic Variation in the B-Type Natriuretic Peptide Pathway Affects BNP Levels. <i>Cardiovascular Drugs and Therapy</i> , 2007, 21, 55-62.	1.3	38
310	Pharmacogenomics of cancer chemotherapy-induced toxicity. <i>The Journal of Supportive Oncology</i> , 2007, 5, 9-14.	2.3	14
311	Pharmacogenetics: using DNA to optimize drug therapy. <i>American Family Physician</i> , 2007, 76, 1179-82.	0.1	20
312	Pharmacogenomics: Challenges and Opportunities. <i>Annals of Internal Medicine</i> , 2006, 145, 749.	2.0	228
313	DNA Repair Pathway Profiling and Microsatellite Instability in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 5104-5111.	3.2	34
314	Pharmacokinetics after Endovascular Lung Perfusion with Cisplatin. <i>Journal of Vascular and Interventional Radiology</i> , 2006, 17, 883-888.	0.2	6
315	Pharmacokinetics: what you need to know. <i>Foundation Years</i> , 2006, 2, 228-232.	0.0	1
316	IMPROVING THE EFFICACY AND SAFETY OF ANTICANCER AGENTS – THE ROLE OF PHARMACOGENETICS. , 2006, , 285-298.		0
317	Applying pharmacogenomics to enhance the use of biomarkers for drug effect and drug safety. <i>Trends in Pharmacological Sciences</i> , 2006, 27, 498-502.	4.0	16
318	A Phase II Study of Irinotecan and Carboplatin in Advanced Non-small Cell Lung Cancer with Pharmacogenomic Analysis: Final Report. <i>Journal of Thoracic Oncology</i> , 2006, 1, 972-978.	0.5	17
319	Î²2-Adrenergic Receptor Genotype Predicts Survival. <i>Journal of Cardiovascular Nursing</i> , 2006, 21, 474-477.	0.6	4
320	A Phase II Study of Irinotecan and Carboplatin in Advanced Non-small Cell Lung Cancer with Pharmacogenomic Analysis: Final Report. <i>Journal of Thoracic Oncology</i> , 2006, 1, 972-978.	0.5	29
321	Defining the opportunity for pharmacogenetic intervention in primary care. <i>Pharmacogenomics</i> , 2006, 7, 61-65.	0.6	49
322	Systems pharmacogenomics in yeast. <i>Pharmacogenomics</i> , 2006, 7, 255-259.	0.6	5
323	Natriuretic peptide receptor 3 genotype modulates the relationship between B-type natriuretic peptide and left ventricular end-diastolic pressure. <i>Therapy: Open Access in Clinical Medicine</i> , 2006, 3, 765-771.	0.2	4
324	Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 80, 282-297.	2.3	201

#	ARTICLE	IF	CITATIONS
325	Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes. <i>Investigational New Drugs</i> , 2006, 24, 393-401.	1.2	46
326	The kinetics and tissue distribution of protein transduction in mice. <i>European Journal of Pharmaceutical Sciences</i> , 2006, 27, 311-319.	1.9	99
327	Methotrexate pharmacogenetics: The first step toward individualized therapy in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2006, 54, 1366-1377.	6.7	122
328	Global pharmacogenetics: giving the genome to the masses. <i>Pharmacogenomics</i> , 2006, 7, 625-631.	0.6	26
329	Pharmacogenetics of alkylator-associated acute myeloid leukemia. <i>Pharmacogenomics</i> , 2006, 7, 719-729.	0.6	10
330	Pharmacogenomics: from bedside to clinical practice. <i>Human Molecular Genetics</i> , 2006, 15, R89-R93.	1.4	64
331	New Developments in the Epidemiology of Cancer Prognosis: Traditional and Molecular Predictors of Treatment Response and Survival. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 2042-2046.	1.1	15
332	Thymidine Phosphorylase and Capecitabine: A Predictive Marker for Therapy Selection?. <i>Journal of Clinical Oncology</i> , 2006, 24, 4051-4053.	0.8	7
333	Clopidogrel Pharmacogenetics. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 1681-1683.	1.1	22
334	Hoosier Oncology Group Randomized Phase II Study of Docetaxel, Vinorelbine, and Estramustine in Combination in Hormone-Refractory Prostate Cancer with Pharmacogenetic Survival Analysis. <i>Clinical Cancer Research</i> , 2006, 12, 6094-6099.	3.2	66
335	The Cancer and Leukemia Group B Pharmacology and Experimental Therapeutics Committee: A Historical Perspective. <i>Clinical Cancer Research</i> , 2006, 12, 3612s-3616s.	3.2	19
336	ABCB1 2677G>T/A Genotype and Paclitaxel Pharmacogenetics in Ovarian Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 4127-4129.	3.2	26
337	Methylation of the DPYD Promoter and Dihydropyrimidine Dehydrogenase Deficiency. <i>Clinical Cancer Research</i> , 2006, 12, 3864-3864.	3.2	20
338	Identification of Candidate Alkylator-Induced Cancer Susceptibility Genes by Whole Genome Scanning in Mice. <i>Cancer Research</i> , 2006, 66, 5029-5038.	0.4	44
339	Hematological Pharmacogenetics. , 2006, , 111-128.		1
340	Natriuretic peptide receptor 3 genotype modulates the relationship between B-type natriuretic peptide and left ventricular end-diastolic pressure. <i>Therapy: Open Access in Clinical Medicine</i> , 2006, 3, 765-771.	0.2	0
341	Individualizing cancer chemotherapy. <i>Clinical Advances in Hematology and Oncology</i> , 2006, 4, 259-61.	0.3	3
342	A phase II study of irinotecan and carboplatin in advanced non-small cell lung cancer with pharmacogenomic analysis: final report. <i>Journal of Thoracic Oncology</i> , 2006, 1, 972-8.	0.5	14

#	ARTICLE	IF	CITATIONS
343	PI3K/Akt/mTOR pathway as a target for cancer therapy. <i>Anti-Cancer Drugs</i> , 2005, 16, 797-803.	0.7	396
344	Pharmacogenetics and Pediatric Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2005, 11, 314-323.	1.0	8
345	Pharmacogenetics goes 3D. <i>Nature Genetics</i> , 2005, 37, 794-795.	9.4	16
346	Contrasting patterns of Y chromosome and mtDNA variation in Africa: evidence for sex-biased demographic processes. <i>European Journal of Human Genetics</i> , 2005, 13, 867-876.	1.4	190
347	A novel CYP2A6*20 allele found in African-American population produces a truncated protein lacking enzymatic activity. <i>Biochemical Pharmacology</i> , 2005, 70, 801-808.	2.0	48
348	Pharmacogenetic influences on treatment response and toxicity in colorectal cancer. <i>Seminars in Oncology</i> , 2005, 32, 113-119.	0.8	17
349	PolyMAPr: Programs for polymorphism database mining, annotation, and functional analysis. <i>Human Mutation</i> , 2005, 25, 110-117.	1.1	37
350	Methotrexate and long-term treatment of rheumatic disease: Comment on the article by Kremer. <i>Arthritis and Rheumatism</i> , 2005, 52, 670-671.	6.7	1
351	CYP3A4 and CYP3A5 genotyping by Pyrosequencing. <i>BMC Medical Genetics</i> , 2005, 6, 19.	2.1	60
352	Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. <i>Thrombosis and Haemostasis</i> , 2005, 93, 700-705.	1.8	176
353	Gene Expression Profiling of the Irinotecan Pathway in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 2053-2062.	3.2	55
354	CHARACTERIZATION OF NOVEL CYP2A6 POLYMORPHIC ALLELES (CYP2A6*18 AND CYP2A6*19) THAT AFFECT ENZYMATIC ACTIVITY. <i>Drug Metabolism and Disposition</i> , 2005, 33, 1202-1210.	1.7	49
355	Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 Polymorphisms with the Pharmacokinetics of Paclitaxel. <i>Clinical Cancer Research</i> , 2005, 11, 8097-8104.	3.2	170
356	CpG Island Methylation of DNA Damage Response Genes in Advanced Ovarian Cancer. <i>Cancer Research</i> , 2005, 65, 8961-8967.	0.4	241
357	Concordance of pharmacogenetic markers in germline and colorectal tumor DNA. <i>Pharmacogenomics</i> , 2005, 6, 873-877.	0.6	42
358	Pyrosequencing of Clinically Relevant Polymorphisms. , 2005, 311, 097-114.		57
359	Pharmacogenomic Discovery Approaches: Will the Real Genes Please Stand Up?. <i>Journal of Clinical Oncology</i> , 2005, 23, 7342-7349.	0.8	43
360	Pharmacogenetic Analysis of Clinically Relevant Genetic Polymorphisms. <i>Clinical Infectious Diseases</i> , 2005, 41, S449-S452.	2.9	6

#	ARTICLE	IF	CITATIONS
361	Differential Expression of the AP-1 Transcription Factor Family Members in Human Colorectal Epithelial and Neuroendocrine Neoplasms. <i>American Journal of Clinical Pathology</i> , 2005, 124, 11-19.	0.4	41
362	COMMENT ON "A FRAMESHIFT MUTATION AND ALTERNATE SPLICING IN HUMAN BRAIN GENERATE A FUNCTIONAL FORM OF THE PSEUDOGENE CYTOCHROME P4502D7 THAT DEMETHYLATES CODEINE TO MORPHINE" Drug Metabolism and Disposition, 2005, 33, 1564-1565.	1.7	5
363	Irinotecan pharmacokinetic and pharmacogenomic alterations induced by methylselenocysteine in human head and neck xenograft tumors. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 843-854.	1.9	12
364	Polymorphism discovery in 51 chemotherapy pathway genes. <i>Human Molecular Genetics</i> , 2005, 14, 3595-3603.	1.4	20
365	A mouse model for developing treatment for secondary liver tumors. <i>International Journal of Oncology</i> , 2005, 27, 113.	1.4	3
366	CEPH individuals are representative of the European American population: implications for pharmacogenetics. <i>Pharmacogenomics</i> , 2005, 6, 59-63.	0.6	17
367	Small inhibitory RNA "a tool for credentialing candidate genes. <i>Pharmacogenomics</i> , 2005, 6, 281-292.	0.6	1
368	Altered Expression of TFF-1 and CES-2 in Barrett's Esophagus and Associated Adenocarcinomas. <i>Neoplasia</i> , 2005, 7, 407-416.	2.3	22
369	Effect of VKORC1 Haplotypes on Transcriptional Regulation and Warfarin Dose. <i>New England Journal of Medicine</i> , 2005, 352, 2285-2293.	13.9	1,348
370	β -Adrenergic Receptor Genotype and Survival Among Patients Receiving β -Blocker Therapy After an Acute Coronary Syndrome. <i>JAMA - Journal of the American Medical Association</i> , 2005, 294, 1526.	3.8	177
371	Variance in the Expression of 5-Fluorouracil Pathway Genes in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 2612-2619.	3.2	64
372	Mechanism-Based Inhibition of Cytochrome P450 3A4 by Therapeutic Drugs. <i>Clinical Pharmacokinetics</i> , 2005, 44, 279-304.	1.6	419
373	The pharmacogenetics of coumarin therapy. <i>Pharmacogenomics</i> , 2005, 6, 503-513.	0.6	86
374	Beta-2 adrenergic receptor genotypes and haplotypes in different ethnic groups. <i>International Journal of Molecular Medicine</i> , 2005, 16, 573-80.	1.8	35
375	Should Screening for DPD Deficiency Be Mandatory before 5-FU Exposure?. <i>Oncology Research and Treatment</i> , 2004, 27, 531-533.	0.8	4
376	Drug pathways: moving beyond single gene pharmacogenetics. <i>Pharmacogenomics</i> , 2004, 5, 139-141.	0.6	20
377	Frequency of compound genotypes associated with β -blocker efficacy in congestive heart failure. <i>Pharmacogenomics</i> , 2004, 5, 553-558.	0.6	9
378	Pharmacogenetics of irinotecan toxicity. <i>Pharmacogenomics</i> , 2004, 5, 835-843.	0.6	71

#	ARTICLE	IF	CITATIONS
379	The Pharmacogenetics of Antiretroviral Therapy: A Review of Studies to Date. <i>Clinical Infectious Diseases</i> , 2004, 39, 98-106.	2.9	34
380	Therapeutic Synergy Between Irinotecan and 5-Fluorouracil against Human Tumor Xenografts. <i>Clinical Cancer Research</i> , 2004, 10, 1121-1129.	3.2	77
381	Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors. <i>International Journal of Oncology</i> , 2004, 24, 893.	1.4	46
382	Candidate gene selection in pharmacogenomics: biology leads the way. <i>Pharmacogenomics</i> , 2004, 5, 1019-1022.	0.6	0
383	Genome-wide discovery of loci influencing chemotherapy cytotoxicity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 11809-11814.	3.3	142
384	ABCG2 Pharmacogenetics. <i>Clinical Cancer Research</i> , 2004, 10, 5889-5894.	3.2	211
385	Irinotecan Pharmacogenetics: Is It Time to Intervene?. <i>Journal of Clinical Oncology</i> , 2004, 22, 1356-1359.	0.8	44
386	Challenges of implementing pharmacogenetics in the critical care environment. <i>Nature Reviews Drug Discovery</i> , 2004, 3, 88-93.	21.5	15
387	Pharmacogenetics: ethical problems and solutions. <i>Nature Reviews Genetics</i> , 2004, 5, 676-680.	7.7	35
388	Pharmacogenetics of tipifarnib (R115777) transport and metabolism in cancer patients. <i>Investigational New Drugs</i> , 2004, 22, 285-289.	1.2	16
389	Distribution of ITPA P32T alleles in multiple world populations. <i>Journal of Human Genetics</i> , 2004, 49, 579-581.	1.1	88
390	The candidate oncogene ZNF217 is frequently amplified in colon cancer. <i>Journal of Pathology</i> , 2004, 204, 282-288.	2.1	51
391	PromoLign: A database for upstream region analysis and SNPs. <i>Human Mutation</i> , 2004, 23, 534-539.	1.1	33
392	Simple and rapid docetaxel assay in plasma by protein precipitation and high-performance liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2004, 804, 263-267.	1.2	45
393	Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype*1. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 76, 38-44.	2.3	222
394	Caution with β 1-adrenergic receptor genotyping*1. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 76, 185-186.	2.3	4
395	A novel polymorphism of human gene has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 76, 519-527.	2.3	75
396	Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. <i>Thrombosis and Haemostasis</i> , 2004, 91, 87-94.	1.8	308

#	ARTICLE	IF	CITATIONS
397	Gene Expression Profiles and Molecular Markers To Predict Recurrence of Dukes' B Colon Cancer. <i>Journal of Clinical Oncology</i> , 2004, 22, 1564-1571.	0.8	411
398	Genotypes associated with myocardial infarction risk are more common in African Americans than in European Americans. <i>Journal of the American College of Cardiology</i> , 2004, 44, 165-167.	1.2	36
399	Compound genotypes associated with beta-blocker efficacy in congestive heart failure are common. <i>Journal of Cardiac Failure</i> , 2004, 10, S57.	0.7	0
400	Sequence variants of natriuretic peptide receptor C are common and their frequency differs between African Americans and European Americans. <i>Journal of Cardiac Failure</i> , 2004, 10, S59.	0.7	4
401	Application of Pharmacogenomics in the Individualization of Chemotherapy for Gastrointestinal Malignancies. <i>Clinical Colorectal Cancer</i> , 2004, 4, S43-S47.	1.0	11
402	Single nucleotide polymorphism profiling across the methotrexate pathway in normal subjects and patients with rheumatoid arthritis. <i>Pharmacogenomics</i> , 2004, 5, 559-569.	0.6	38
403	Novel human CYP2A6 alleles confound gene deletion analysis. <i>FEBS Letters</i> , 2004, 569, 75-81.	1.3	44
404	Evaluation of epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy: Is there a need for a more rational design?. <i>European Journal of Cancer</i> , 2004, 40, 1807-1809.	1.3	9
405	Pharmacogenomic assessment of carboxylesterases 1 and 2. <i>Genomics</i> , 2004, 84, 661-668.	1.3	105
406	Relationship between Red Blood Cell Thiopurine Methyltransferase Activity and Myelotoxicity in Dogs Receiving Azathioprine. <i>Journal of Veterinary Internal Medicine</i> , 2004, 18, 339-345.	0.6	15
407	CYP3A5 Polymorphism and the Ethnic Differences in Cyclosporine Pharmacokinetics in Healthy Subjects 1. <i>Therapeutic Drug Monitoring</i> , 2004, 26, 524-528.	1.0	67
408	Analysis of variation in mouse TPMT genotype, expression and activity. <i>Pharmacogenetics and Genomics</i> , 2004, 14, 247-254.	5.7	9
409	A novel polymorphism in the promoter region of human UGT1A9 gene (UGT1A9*22) and its effects on the transcriptional activity. <i>Pharmacogenetics and Genomics</i> , 2004, 14, 329-332.	5.7	118
410	Use of pharmacogenetics to guide warfarin therapy. <i>Drugs of Today</i> , 2004, 40, 247.	2.4	7
411	Relationship between red blood cell thiopurine methyltransferase activity and myelotoxicity in dogs receiving azathioprine. <i>Journal of Veterinary Internal Medicine</i> , 2004, 18, 339-45.	0.6	9
412	Pharmacogenomics: The Influence of Genomic Variation on Drug Response. <i>Current Topics in Medicinal Chemistry</i> , 2004, 4, 1397-1407.	1.0	31
413	Length and somatic mosaicism of CAG and CGN repeats in the androgen receptor gene and the risk of prostate cancer in men with benign prostatic hyperplasia. <i>Annals of Saudi Medicine</i> , 2004, 24, 21-26.	0.5	11
414	Endovascular lung perfusion using high-dose cisplatin: uptake and DNA adduct formation in an animal model. <i>Oncology Reports</i> , 2004, 11, 237-43.	1.2	4

#	ARTICLE	IF	CITATIONS
415	Vitamin D receptor, HER-2 polymorphisms and risk of prostate cancer in men with benign prostate hyperplasia. <i>Journal of King Abdulaziz University, Islamic Economics</i> , 2004, 25, 447-51.	0.5	28
416	Cancer pharmacogenomics: current and future applications. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2003, 1603, 99-111.	3.3	67
417	Pharmacokinetics for the Prescriber. <i>Medicine</i> , 2003, 31, 11-15.	0.2	3
418	Disulfiram-mediated inhibition of NF- κ B activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines. <i>International Journal of Cancer</i> , 2003, 104, 504-511.	2.3	206
419	Cancer pharmacogenetics: polymorphisms, pathways and beyond. <i>Nature Reviews Cancer</i> , 2003, 3, 912-920.	12.8	187
420	Cancer Pharmacogenomics: SNPs, Chips, and the Individual Patient. <i>Cancer Investigation</i> , 2003, 21, 630-640.	0.6	58
421	Pharmacogenetic Analysis of Clinically Relevant Genetic Polymorphisms. , 2003, 85, 225-238.		17
422	Pharmacogenomics â€™ Drug Disposition, Drug Targets, and Side Effects. <i>New England Journal of Medicine</i> , 2003, 348, 538-549.	13.9	1,609
423	Using genome-wide mapping in the mouse to identify genes that influence drug response. <i>Trends in Pharmacological Sciences</i> , 2003, 24, 55-58.	4.0	14
424	Use of Pyrosequencing to Detect Clinically Relevant Polymorphisms in Dihydropyrimidine Dehydrogenase. <i>Clinical Chemistry</i> , 2003, 49, 1661-1664.	1.5	34
425	A pilot study of high-throughput, sequence-based mutational profiling of primary human acute myeloid leukemia cell genomes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 14275-14280.	3.3	55
426	A mouse-based strategy for cyclophosphamide pharmacogenomic discovery. <i>Journal of Applied Physiology</i> , 2003, 95, 1352-1360.	1.2	27
427	Molecular predictors of prognosis and response to therapy in colorectal cancer. <i>Cancer Chemotherapy and Biological Response Modifiers</i> , 2003, 21, 791-801.	0.5	7
428	Irinotecan pathway genotype analysis to predict pharmacokinetics. <i>Clinical Cancer Research</i> , 2003, 9, 3246-53.	3.2	189
429	Ferredoxin reductase: pharmacogenomic assessment in colorectal cancer. <i>Cancer Research</i> , 2003, 63, 6170-3.	0.4	21
430	Using genetic variation to optimize cancer chemotherapy. <i>Clinical Advances in Hematology and Oncology</i> , 2003, 1, 107-11.	0.3	7
431	Evaluation of NQO1 gene expression and variant allele in human NSCLC tumors and matched normal lung tissue. <i>International Journal of Oncology</i> , 2002, 21, 1119.	1.4	16
432	Murine pharmacogenomics: using the mouse to understand the genetics of drug therapy. <i>Pharmacogenomics</i> , 2002, 3, 781-790.	0.6	10

#	ARTICLE	IF	CITATIONS
433	Title is missing!. Applied Immunohistochemistry & Molecular Morphology, 2002, 10, 374-380.	2.0	23
434	CYP3A4 promoter variant is associated with prostate cancer risk in men with benign prostate hyperplasia. Oncology Reports, 2002, 9, 653.	1.2	16
435	Comprehensive Evaluation of Carboxylesterase-2 Expression in Normal Human Tissues Using Tissue Array Analysis. Applied Immunohistochemistry and Molecular Morphology, 2002, 10, 374-380.	0.6	34
436	Individualized cancer therapy: molecular approaches to the prediction of tumor response. Expert Review of Anticancer Therapy, 2002, 2, 113-119.	1.1	15
437	Topoisomerase I protein expression in primary colorectal cancer and lymph node metastases. Human Pathology, 2002, 33, 1114-1119.	1.1	28
438	Genetic Strategies to Individualize Supportive Care. Journal of Clinical Oncology, 2002, 20, 2765-2767.	0.8	11
439	Genetic basis of drug metabolism. American Journal of Health-System Pharmacy, 2002, 59, 2061-2069.	0.5	107
440	SNP databases and pharmacogenetics: great start, but a long way to go. Human Mutation, 2002, 20, 174-179.	1.1	62
441	Analysis of key cell-cycle checkpoint proteins in colorectal tumours. Journal of Pathology, 2002, 196, 386-393.	2.1	75
442	The thiopurine S-methyltransferase gene locus " implications for clinical pharmacogenomics. Pharmacogenomics, 2002, 3, 89-98.	0.6	275
443	Effect of grapefruit juice intake on etoposide bioavailability. European Journal of Clinical Pharmacology, 2002, 58, 491-494.	0.8	73
444	Primary colorectal tumour is not an accurate predictor of thymidylate synthase in lymph node metastasis. Oncology Reports, 2002, 9, 231-4.	1.2	20
445	CYP3A4 promoter variant is associated with prostate cancer risk in men with benign prostate hyperplasia. Oncology Reports, 2002, 9, 653-5.	1.2	37
446	Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan. Clinical Cancer Research, 2002, 8, 2605-11.	3.2	210
447	Evaluation of NQO1 gene expression and variant allele in human NSCLC tumors and matched normal lung tissue. International Journal of Oncology, 2002, 21, 1119-24.	1.4	14
448	Thymidylate Synthase Pharmacogenetics in Colorectal Cancer. Clinical Colorectal Cancer, 2001, 1, 175-178.	1.0	83
449	PHARMACOGENOMICS: Unlocking the Human Genome for Better Drug Therapy. Annual Review of Pharmacology and Toxicology, 2001, 41, 101-121.	4.2	302
450	Allelotype frequency of the thiopurine methyltransferase (TPMT) gene in Japanese. Pharmacogenetics and Genomics, 2001, 11, 275-278.	5.7	103

#	ARTICLE	IF	CITATIONS
451	MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. <i>Pharmacogenetics and Genomics</i> , 2001, 11, 217-221.	5.7	373
452	The Geographic Distribution of Monoamine Oxidase Haplotypes Supports a Bottleneck During the Dispersion of Modern Humans from Africa. <i>Journal of Molecular Evolution</i> , 2001, 52, 157-163.	0.8	21
453	Thymidine phosphorylase and dihydropyrimidine dehydrogenase protein expression in colorectal cancer. <i>International Journal of Cancer</i> , 2001, 94, 297-301.	2.3	23
454	Pharmacogenetics: more than skin deep. <i>Nature Genetics</i> , 2001, 29, 247-248.	9.4	32
455	Cytochrome P450 CYP1B1 protein expression:. <i>Biochemical Pharmacology</i> , 2001, 62, 207-212.	2.0	153
456	Distinct differences in a cyclin D1 single nucleotide polymorphism between ethnic groups. <i>GeneScreen</i> , 2001, 1, 139-142.	0.7	5
457	Analysis of uracil DNA glycosylase in human colorectal cancer. <i>International Journal of Oncology</i> , 2001, 18, 393-9.	1.4	11
458	Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. <i>International Journal of Oncology</i> , 2001, 19, 383-6.	1.4	81
459	CYP3A4 promoter variant in Saudi, Ghanaian and Scottish Caucasian populations. <i>Pharmacogenetics and Genomics</i> , 2000, 10, 753-756.	5.7	45
460	Pharmacogenetics of catechol-O-methyltransferase: Frequency of low activity allele in a Ghanaian population. <i>Human Mutation</i> , 2000, 16, 445-446.	1.1	23
461	Novel thymidylate synthase enhancer region alleles in African populations. <i>Human Mutation</i> , 2000, 16, 528-528.	1.1	100
462	Evaluation of dihydropyrimidine dehydrogenase activity in South-west Asian, Kenyan and Ghanaian populations. <i>British Journal of Clinical Pharmacology</i> , 2000, 50, 269-272.	1.1	25
463	Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. <i>Leukemia</i> , 2000, 14, 567-572.	3.3	422
464	Characterization of the Topoisomerase I Locus in Human Colorectal Cancer. <i>Cancer Genetics and Cytogenetics</i> , 2000, 121, 56-60.	1.0	25
465	Phase I study of AG2034, a targeted GARFT inhibitor, administered once every 3 weeks. <i>Cancer Chemotherapy and Pharmacology</i> , 2000, 45, 423-427.	1.1	10
466	Re: Population-Based, Case-Control Study of HER2 Genetic Polymorphism and Breast Cancer Risk. <i>Journal of the National Cancer Institute</i> , 2000, 92, 1947-1947.	3.0	30
467	5-Fluorouracil Metabolizing Enzymes. , 1999, 28, 111-120.		1
468	Analysis of thiopurine methyltransferase variant alleles in childhood acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 1999, 105, 696-700.	1.2	108

#	ARTICLE	IF	CITATIONS
469	Ethnic Variation in the Thymidylate Synthase Enhancer Region Polymorphism among Caucasian and Asian Populations. <i>Genomics</i> , 1999, 58, 310-312.	1.3	194
470	The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. <i>Pharmacogenetics and Genomics</i> , 1999, 9, 37-42.	5.7	354
471	Ethnic differences in thiopurine methyltransferase pharmacogenetics. <i>Pharmacogenetics and Genomics</i> , 1999, 9, 773-776.	5.7	167
472	Eniluracil Treatment Completely Inactivates Dihydropyrimidine Dehydrogenase in Colorectal Tumors. <i>Journal of Clinical Oncology</i> , 1999, 17, 2439-2439.	0.8	60
473	Thiopurine Methyltransferase Genotype and the Toxicity of Azathioprine in Japanese.. <i>Internal Medicine</i> , 1999, 38, 944-947.	0.3	54
474	Ethnic differences in thiopurine methyltransferase pharmacogenetics. <i>Pharmacogenetics and Genomics</i> , 1999, 9, 773-776.	0.7	3
475	Evaluation of the linearity of docetaxel pharmacokinetics. <i>Cancer Chemotherapy and Pharmacology</i> , 1998, 42, 155-159.	1.1	39
476	Clinically relevant drug-drug interactions in oncology. <i>British Journal of Clinical Pharmacology</i> , 1998, 45, 539-544.	1.1	70
477	Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects. <i>British Journal of Clinical Pharmacology</i> , 1998, 46, 151-156.	1.1	113
478	Characterization of the Human Dihydropyrimidine Dehydrogenase Gene. <i>Genomics</i> , 1998, 51, 391-400.	1.3	158
479	Ethnic differences in catechol O-methyltransferase pharmacogenetics. <i>Pharmacogenetics and Genomics</i> , 1998, 8, 195-200.	5.7	14
480	Thiopurine Methyltransferase Genotype Predicts Therapy-Limiting Severe Toxicity from Azathioprine. <i>Annals of Internal Medicine</i> , 1998, 129, 716.	2.0	334
481	Liver Dihydropyrimidine Dehydrogenase Activity in Human, Cynomolgus Monkey, Rhesus Monkey, Dog, Rat and Mouse. <i>Pharmacology</i> , 1998, 56, 276-280.	0.9	12
482	Therapeutic drug monitoring opportunities in cancer therapy. , 1997, 74, 39-54.		27
483	McLeod et al. reply. <i>Trends in Pharmacological Sciences</i> , 1996, 17, 107.	4.0	7
484	METABOLISM OF AZATHIOPRINE. <i>Transplantation</i> , 1996, 61, 1425.	0.5	2
485	Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity.. <i>Journal of Clinical Investigation</i> , 1996, 98, 610-615.	3.9	312
486	Higher activity of polymorphic thiopurine S-methyltransferase in erythrocytes from neonates compared to adults. <i>Pharmacogenetics and Genomics</i> , 1995, 5, 281-286.	5.7	74

#	ARTICLE	IF	CITATIONS
487	Topoisomerase I and II activity in human breast, cervix, lung and colon cancer. <i>International Journal of Cancer</i> , 1994, 59, 607-611.	2.3	71
488	High-dose dextromethorphan in amyotrophic lateral sclerosis: Phase I safety and pharmacokinetic studies. <i>Annals of Neurology</i> , 1994, 36, 920-924.	2.8	63
489	Thiopurine methyltransferase activity in American white subjects and black subjects. <i>Clinical Pharmacology and Therapeutics</i> , 1994, 55, 15-20.	2.3	242
490	Etoposide pharmacokinetics and pharmacodynamics after acute and chronic exposure to cisplatin. <i>Clinical Pharmacology and Therapeutics</i> , 1994, 56, 503-511.	2.3	47
491	Concordance of phenotype and genotype for CYP2D6. <i>Clinical Pharmacology and Therapeutics</i> , 1994, 56, 463-463.	2.3	1
492	Stability of Cyclosporine in Dextrose 5%, NaCl 0.9%, Dextrose/Amino Acid Solution, and Lipid Emulsion. <i>Annals of Pharmacotherapy</i> , 1992, 26, 172-175.	0.9	8
493	Stability of etoposide solution for oral use. <i>American Journal of Health-System Pharmacy</i> , 1992, 49, 2784-2785.	0.5	3
494	Somnolence, hypotension, and metabolic acidosis following high-dose teniposide treatment in children with leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , 1991, 29, 150-154.	1.1	21
495	Ethnicity and Pharmacogenomics. , 0, , 489-514.		1
496	Expression of matrix metalloproteinases 1, 2, 9 and their tissue inhibitors in stage II non-small cell lung cancer: Implications for MMP inhibition therapy. <i>Oncology Reports</i> , 0, , .	1.2	16
497	Primary colorectal tumour is not an accurate predictor of thymidylate synthase in lymph node metastasis. <i>Oncology Reports</i> , 0, , .	1.2	14
498	Endovascular lung perfusion using high-dose cisplatin: Uptake and DNA adduct formation in an animal model. <i>Oncology Reports</i> , 0, , .	1.2	1